Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy?
The Motley Fool · Matthew Benjamin ·
The stock is expensive, but the potential market for GLP-1 drugs is likely much larger than forecast.
Read the full story at The Motley Fool · All coverage of this story